BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Radiopharmaceuticals
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, September 22, 2023
Home » Authors » Amanda Lanier

Amanda Lanier

Articles

ARTICLES

Red wooden approved stamp
Biopharma regulatory actions and approvals August 2023

US FDA approvals up 16% over last year

Sep. 22, 2023
By Amanda Lanier
No Comments
Approvals from the U.S. FDA are up more than 16% from last year, with 113 drugs approved in the first eight months of 2023. New approvals include two different treatments for relapsed or refractory multiple myeloma, two treatments for ultra-rare diseases and a biosimilar to Biogen Inc.’s Tysabri. In August the FDA greenlighted 13 drugs, approving three NDAs, six BLAs, two supplemental NDAs and two supplemental BLAs.
Read More
Illustration of big fish eating three smaller fish
Biopharma deals August 2023

Lilly closes two $1B+ acquisitions in August as M&As pace similar to last year

Sep. 15, 2023
By Amanda Lanier
No Comments
Biopharma deal values through August are down 13.05% year-over-year, while the number of deals has fallen by 18.51% compared to 2022. M&A value, meanwhile, is down just 3.6% from last year. Through August, 2023 saw 885 biopharma deals worth $111.87 billion, compared to 1,086 deals totaling $128.66 billion in the same period in 2022. The first eight months of 2021 saw 1,386 deals worth $121.22 billion, 1,381 deals valued at $129.96 billion in 2020 and 1,051 deals worth $111.93 billion in 2019.
Read More

Exor-Philips deal tops charts as industry’s largest; overall med-tech deals up 90% YOY

Sep. 15, 2023
By Amanda Lanier
No Comments

Med-tech deal values continued their upward swing, increasing nearly 90% from last year. Med-tech M&A volume and value remained in a slump compared to the previous two years, though values are higher than 2020.


Read More
Global map, financial charts

Two med-tech IPOs in August bring 2023 total to five

Sep. 11, 2023
By Amanda Lanier
No Comments
In August 2023, med-tech firms raised a total of $1.88 billion through 27 transactions, an increase of 94.12% from the $971 million raised in July. Value is down 42.83%, however, from the $3.3 billion raised in August 2022. The volume of med-tech financings is tracking at an average of 41 per month in 2023, down from an average of 43 per month in 2022, 59 per month through 2021 and 60 per month in 2020.
Read More
Coin stacks, dollar signs and up arrow
Biopharma financings August 2023

Biopharma financings up from last year with $42.8B raised through August 2023

Sep. 8, 2023
By Amanda Lanier
No Comments
In August 2023 biopharma companies raised a collective $4.02 billion through 86 transactions, down from the previous seven months’ average of $5.53 billion.
Read More
Nonprofit stamp
Biopharma nonprofit deals and grants August 2023

Biopharmas receive $1.43B in BARDA grants in 2023

Sep. 5, 2023
By Amanda Lanier
No Comments
Biopharma grants are up nearly 150% compared to the same time period last year, largely due to a number of $100 million-plus grants from the Biomedical Advanced Research and Development Authority (BARDA). Meanwhile, nonprofit deal value has declined year-over-year, with the number of transactions down 42.21%.
Read More
Syringe and capsules atop lab chart
Biopharma clinical updates July 2023

Clinical trial data down from 2021 but up 18% from 2019

Aug. 29, 2023
By Amanda Lanier
No Comments
The first seven months of 2023 saw clinical trial data up 1.43% compared to the same time period last year. From January through July this year, BioWorld reported on 2,064 drugs in phase I-III, compared to 2,035 in the same time period in 2022. The number of trial updates is down 14.07% from the 2,402 in 2021 and down from 2020’s 2,096, but up 18.15% from 2019’s 1,747.
Read More
Syringe and capsules atop lab chart
Biopharma clinical updates July 2023

Clinical trial data down from 2021 but up 18% from 2019

Aug. 25, 2023
By Amanda Lanier
No Comments
The first seven months of 2023 saw clinical trial data up 1.43% compared to the same time period last year. From January through July this year, BioWorld reported on 2,064 drugs in phase I-III, compared to 2,035 in the same time period in 2022. The number of trial updates is down 14.07% from the 2,402 in 2021 and down from 2020’s 2,096, but up 18.15% from 2019’s 1,747.
Read More
Approved stamp
Biopharma regulatory actions and approvals July 2023

US FDA approvals up 20% year-over-year, average 14 a month in 2023

Aug. 18, 2023
By Amanda Lanier
No Comments
Drug approvals by the U.S. FDA increased 20.48% compared to the first seven months of 2022, even with July approvals slightly down to 13 from the previous six months’ average of 14.5 per month. Worldwide approvals from January to July are down 13.8% from the same period last year.
Read More
Concept of business partnership
Biopharma deals July 2023

First seven months of 2023 sees $105.4B in biopharma deals and $37.6B in M&As

Aug. 15, 2023
By Amanda Lanier
No Comments
The June dip in biopharma deal value was short-lived, with July seeing 106 deals worth $17.57 billion, up 72.03% from $10.22 billion in July 2022.
Read More
View All Articles by Amanda Lanier

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Sept. 22, 2023.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for September 22, 2023.
  • Hands holding torn contract

    Quite a fix: Orthofix sacks three top execs

    BioWorld MedTech
    Orthofix Medical Inc. terminated its CEO, chief financial officer and chief legal officer in a move that plunged the stock from $18.63 at Monday’s close to $13.01...
  • New NLRP3 inflammasome inhibitors named in PTC Therapeutics patent

    BioWorld Science
    PTC Therapeutics Inc. has patented new NLRP3 inflammasome inhibitors reported to be useful...
  • Illustration of Alzheimer’s in the brain.

    Study identifies cause of death for Alzheimer’s neurons

    BioWorld
    By creating a new mouse model of Alzheimer’s disease that better recapitulated how the disease plays out in humans, investigators at KU Leuven have gained new...
BioFuture ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing